

EDUCATIONAL MATERIALS

Dissemination of educational materials for Deferasirox SUN

90, 180, 360 mg film-coated tablets

NL/H/5582/001-003/DC

PLGB 14894/0812-0814

COMMUNICATION PLAN	
Product name/API	Deferasirox 90, 180, 360 mg film-coated tablets
Marketing Authorization Holder	Sun Pharma UK Ltd
Educational Materials	<ul style="list-style-type: none">• Educational materials for physicians (which also includes a prescriber checklist) and• Patient information pack
Approval date of Educational Materials / RMP version nr.	Approval date: 03-June-2024 <i>UK_RMP_DEFE-2023-vs 0.1 from 20-Dec-2023</i>
Objective and justification of why needed:	<ul style="list-style-type: none">• to provide detailed information on posology and required monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment.
Target recipient	all healthcare professionals and patients who are expected to prescribe, dispense and use deferasirox
Dissemination mode	Digital: placing on web-site https://sunpharma.com/united-kingdom-educational-materials/ and https://www.medicines.org.uk/emc Paper copy: on request.
Dissemination timeline	Before the launch of the product